Bridging the scientific field and communities where research happens
HIV prevention research and development is accelerating, with more options available than ever before. But progress toward crucial targets to end the epidemic and prepare for future ones has been far too slow. New leadership, research, and commitments at the global, national, and local levels bring power and potential to strengthen and advance HIV prevention and global health equity, however, but we need to ensure that new policies and product access initiatives are inclusive and donors and decision makers are accountable.
AVAC tracks important issues, in research, policy, financing, news headlines and more. With colleagues and partners, we analyze the data, issues, policy and perspectives, and we translate it into useful and usable resources that all can use to inform their work. We do this by:
AVAC is tracking the impacts and consequences of the new US administration actions to dismantle foreign aid and the retreat from the US’ commitments to science and global health.
factsheet
As more next-generation PrEP options become available, HIV prevention research is shifting away from large, multi-year efficacy trials toward pharmacokinetic (PK) and bioequivalence (BE) studies — which test whether a new formulation behaves in the body like a product already proven to work. This primer explains the shift and what it means for advocates.
factsheet
The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers accelerate equitable access to LEN for PrEP. The checklist is designed to support faster, community-centered rollout ahead of broader generic availability in 2027.
presentation
For HIV Vaccine Awareness Day, AVAC’s latest infographics — covering preventive vaccines, bNAbs, the HIV prevention research pipeline, and the impact of US funding cuts — are available as easy-to-use slides.
From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.
Linking journalists with researchers, civil society, policy makers and regulators for accurate and insightful reporting on HIV, COVID and global health equity.
A one-stop online clearinghouse for resources and information to help the global community effectively deliver proven methods of PrEP to everyone who needs it.
Tracking investments and funding trends in HIV prevention and cure R&D.
Gilead, Unitaid and the US National Institutes of Health are funding 36 ongoing studies to investigate implementation outcomes, rapid initiation and real-life use of injectable lenacapavir (LEN) for PrEP in 9 countries. Gilead’s INCLUSION program (INCLUSION Global in Africa and Asia and INCLUSION-US in the United States) accounts for 26 of these studies. This table provides details on the INCLUSION Global projects planned for 2026-2028 in 7 LEN early adopter countries.
This week, the US Senate Committee on Homeland Security & Governmental Affairs voted along party lines to hold Anthony Fauci in contempt of Congress for his refusal to answer questions during last week’s hearing on the COVID-19 response testimony – while it was rumored that Steven Quay, a lab-leak proponent, is in line for Fauci’s old job. At the same time, the US Senate Appropriations Committee did step up to stop the White House OMB’s politicization of federal research grants. There’s also – finally – a new leader of the US Centers for Disease Control and Prevention (CDC). And the HIV/AIDS community is unpacking major themes emerging from the AIDS 2026 conference.
For those presenting at AIDS 2026, AVAC’s latest infographics on the research and development pipeline, prevention options, and the impact of US funding cuts can be accessed here. We hope these are useful for presentations and discussions at the conference and beyond.
